form8k-pipelineandmustard.htm
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): November 5, 2007
AEOLUS
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or
other jurisdiction of incorporation)
0-50481
56-1953785
(Commission
File
Number) (IRS
Employer ID Number)
23811
Inverness Place
Laguna
Niguel, California 92677
(Address
of Principal Executive Offices, Including Zip Code)
949-481-9825
(Registrant’s
Telephone Number, Including Area Code)
__________________
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
£ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
£
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
£
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
7.01 Regulation FD Disclosure.
On
November 5, 2007, Aeolus Pharmaceuticals, Inc. (“Aeolus”) provided an update on
its drug development program and on November 7, 2007, Aeolus reported results
of
a pre-clinical study of AEOL 10150 for the treatment of mustard gas
exposure.
Copies
of
the press releases issued by Aeolus on November 5, 2007 and November 7, 2007
announcing these events are attached as Exhibit 99.1 and 99.2, respectively,
to
this Current Report on Form 8-K.
Item
9.01. Financial Statements and Exhibits.
| Exhbit
99.1 |
Press
Release dated November 5, 2007 |
| Exhibit
99.2 |
Press
Release dated November 7, 2007 |
SIGNATURE
Pursuant
to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this Report
to
be signed on its behalf by the undersigned thereunto duly
authorized.
AEOLUS
PHARMACEUTICALS,
INC.
Date: November
7, 2007
/s/
Michael P.
McManus___________________
Michael
P. McManus
Chief
Financial Officer, Treasurer and Secretary